DCM
LGND icon

Dupont Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Dupont Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,700
Closed -$467K – 1775
2021
Q2 		$467K Buy
5,700
+1,019
+22% +$84.8K 0.01% 1040
2021
Q1 		$445K Sell
4,681
-909
-16% -$85.9K 0.01% 996
2020
Q4 		$347K Buy
5,590
+585
+12% +$33.4K 0.01% 988
2020
Q3 		$298K Buy
5,005
+571
+13% +$39K 0.01% 975
2020
Q2 		$309K Buy
4,434
+3,196
+258% +$203K 0.01% 959
2020
Q1 		$56K Buy
+1,238
New +$70.2K ﹤0.01% 1238
2019
Q3 		– Sell
-3,418
Closed -$243K – 1236
2019
Q2 		$243K Sell
3,418
-32,645
-91% -$2.4M 0.01% 1058
2019
Q1 		$2.83M Buy
36,063
+10,399
+41% +$788K 0.06% 285
2018
Q4 		$2.17M Sell
25,664
-1,074
-4% -$114K 0.05% 333
2018
Q3 		$4.58M Buy
26,738
+7,568
+39% +$1.14M 0.1% 190
2018
Q2 		$2.48M Buy
19,170
+3,382
+21% +$377K 0.06% 297
2018
Q1 		$1.63M Sell
15,788
-4,189
-21% -$414K 0.04% 389
2017
Q4 		$1.71M Hold
19,977
– – 0.04% 395
2017
Q3 		$1.7M Hold
19,977
– – 0.04% 400
2017
Q2 		$1.51M Hold
19,977
– – 0.03% 435
2017
Q1 		$1.32M Buy
19,977
+6,348
+47% +$418K 0.03% 452
2016
Q4 		$864K Buy
13,629
+7,286
+115% +$460K 0.02% 533
2016
Q3 		$404K Sell
6,343
-8,373
-57% -$615K 0.01% 591
2016
Q2 		$1.09M Sell
14,716
-15,186
-51% -$1.13M 0.02% 421
2016
Q1 		$2M Hold
29,902
– – 0.05% 319
2015
Q4 		$2.02M Hold
29,902
– – 0.05% 337
2015
Q3 		$1.6M Buy
29,902
+11,628
+64% +$706K 0.04% 369
2015
Q2 		$1.15M Hold
18,274
– – 0.02% 417
2015
Q1 		$879K Hold
18,274
– – 0.02% 459
2014
Q4 		$607K Hold
18,274
– – 0.01% 529
2014
Q3 		$536K Buy
18,274
+7,101
+64% +$236K 0.01% 552
2014
Q2 		$434K Buy
+11,173
New +$453K 0.01% 587

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Dupont Capital Management's LGND Position: Q3 2021 in Review

Dupont Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2021, closing a stake of 5,700 shares — an estimated $467K sold.

Dupont Capital Management first reported a position in LGND in Q2 2014 and held it in 27 quarters. The position peaked at $4.58M in Q3 2018. 207 funds tracked by Wall St. Rank hold LGND as of Q3 2021.

  • Dupont Capital Management reported no remaining Ligand Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Dupont Capital Management sold 5,700 Ligand Pharmaceuticals shares in Q3 2021, an estimated $467K.
  • Dupont Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2014 and held it in 27 quarters.
  • Dupont Capital Management's Ligand Pharmaceuticals position peaked at $4.58M in Q3 2018.
  • 207 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2021.

Based on Dupont Capital Management's 13F filing for Q3 2021, filed 3 Nov 2021.